CD274 and autoimmune disease: Safety and efficacy of anti-PD-1/anti-PD-L1 therapy in cancer patients affected by autoimmune disorders have been shown in various series: rates of irAEs and autoimmune flare were consistent, ranging from 23% to 44%, and efficacy did not differ from clinical trials in patients without autoimmune disorders.